全国性回顾性分析:帕金森病患者中先进疗法的联合应用
该研究在德国22个帕金森病中心回顾性收集116例患者共148次先进疗法调整数据,评估同时或序贯联合脑深部电刺激或泵疗法的临床结局、副作用及调整原因;结果显示调整后MDS-UPDRS第三部分中位下降4.0分、第四部分下降6.0分、第四部分关期条目下降1.0分,主观临床结局改善且副作用发生率下降,主要调整原因为症状控制不足和既往治疗副作用。
要点
- 调整或联合先进疗法与MDS-UPDRS第三部分中位下降4.0分、第四部分下降6.0分相关。
- 调整或联合先进疗法与MDS-UPDRS第四部分关期条目中位下降1.0分相关。
- 主要调整原因为既往治疗症状控制不足和副作用,联合方案选择应依据主导症状。
核心结论
- 当一种先进疗法疗效不足或副作用明显时,调整或联合先进疗法可能有益。
- 联合先进疗法的结局与首次引入先进疗法时的临床获益相当。
- 附加的先进疗法应根据主导临床症候和不良反应选择。
- 需要前瞻性试验来确认这一探索性病例收集的结果。
研究设计与样本
- 全国性回顾性病例收集,通过模块化问卷在德国22个帕金森病中心基于临床记录采集数据。
- 共纳入116例患者,评估自2005年以来同时或序贯的先进疗法联合,共148次先进疗法调整。
- 数据评估从第二种先进疗法启动时开始。
主要发现
- 148次先进疗法调整与客观临床结局显著改善相关:MDS-UPDRS第三部分中位下降4.0分(p<0.001)。
- MDS-UPDRS第四部分中位下降6.0分(p<0.001),MDS-UPDRS第四部分关期条目中位下降1.0分(p<0.001)。
- 主观临床结局改善且副作用发生率下降。
- 先进疗法调整的主要原因为既往治疗的症状控制不足和副作用。
- 亚组分析提示:以异动症为主的患者加用脑深部电刺激,以其他主要运动症状为主的患者加用左旋多巴/卡比多巴肠凝胶,以关期为主的患者加用左旋多巴/卡比多巴肠凝胶或持续皮下阿扑吗啡输注。
关键数值与推荐
- MDS-UPDRS第三部分中位下降4.0分(p<0.001)。
- MDS-UPDRS第四部分中位下降6.0分(p<0.001)。
- MDS-UPDRS第四部分关期条目中位下降1.0分(p<0.001)。
临床怎么用
- 当一种先进疗法疗效不足或副作用明显时,可考虑调整或联合先进疗法。
- 附加的先进疗法应根据主导临床症候和不良反应选择。
- 亚组分析提示,以异动症为主者可加用脑深部电刺激,以其他主要运动症状为主者可加用左旋多巴/卡比多巴肠凝胶,以关期为主者可加用左旋多巴/卡比多巴肠凝胶或持续皮下阿扑吗啡输注。
局限性
- 当前关于调整或联合先进疗法的知识多限于回顾性和小规模研究。
- 本研究为回顾性病例收集。
- 需要前瞻性试验来确认这一探索性病例收集的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Advanced therapies (ATs; deep brain stimulation [DBS] or pump therapies: continuous subcutaneous apomorphine infusion [CSAI], levodopa/carbidopa intestinal gel [LCIG]) are used in later stages of Parkinson disease (PD). However, decreasing efficacy over time and/or side effects may require an AT change or combination in individual patients. Current knowledge about changing or combining ATs is limited to mostly retrospective and small-scale studies. The nationwide case collection Combinations of Advanced Therapies in PD assessed simultaneous or sequential AT combinations in Germany since 2005 to analyze their clinical outcome, their side effects, and the reasons for AT modifications. METHODS: Data were acquired retrospectively by modular questionnaires in 22 PD centers throughout Germany based on clinical records and comprised general information about the centers/patients, clinical (Mini-Mental Status Test/Montréal Cognitive Assessment, Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS], side effects, reasons for AT modification), and therapeutical (ATs with specifications, oral medication) data. Data assessment started with initiation of the second AT. RESULTS: A total of 148 AT modifications in 116 patients were associated with significantly improved objective (median decrease of MDS-UPDRS Part III 4.0 points [p < 0.001], of MDS-UPDRS Part IV 6.0 points [p < 0.001], of MDS-UPDRS Part IV-off-time item 1.0 points [p < 0.001]) and subjective clinical outcome and decreasing side effect rates. Main reasons for an AT modification were insufficient symptom control and side effects of the previous therapy. Subgroup analyses suggest addition of DBS in AT patients with leading dyskinesia, addition of LCIG for leading other cardinal motor symptoms, and addition of LCIG or CSAI for dominant off-time. The most long-lasting therapy-until requiring a modification-was DBS. DISCUSSION: Changing or combining ATs may be beneficial when 1 AT is insufficient in efficacy or side effects. The outcome of an AT combination is comparable with the clinical benefit by introducing the first AT. The added AT should be chosen dependent on dominant clinical symptoms and adverse effects. Furthermore, prospective trials are needed to confirm the results of this exploratory case collection. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that, in patients with PD, changing or combining ATs is associated with an improvement in the MDS-UPDRS or subjective symptom reporting.
引用
- Pürner D, Hormozi M, Weiß D, et al. Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease. Neurology. 2023. PMID: 37914414. doi:10.1212/WNL.0000000000207858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。